Multi-endpoint in vitro toxicological assessment of snus and tobacco-free nicotine pouch extracts

Fan Yu, Emma Bishop, Fabio Miazzi, Rhian Evans, David Smart, Damien Breheny and David Thorne

B.A.T (Investments) Ltd., GR&D Centre, Regents Park Road, Southampton, SO15 8TL, UK

Introduction

'Modern' oral tobacco-free nicotine pouches (NPs) are a nicotine containing product similar in appearance and concept to Swedish snus.

A three-step approach was taken to analyse biological effects of NPs and snus extracts *in vitro*. ToxTracker was used to screen for biomarkers for oxidative stress, cell stress, protein damage and DNA damage.

Methodology

1 Study Design

1. *In vitro* disease assessment
2. Regulatory toxicological assessment
3. Potential signalling pathways or inflammatory response

Figure 1. A three-step approach to assess the biological effects of tobacco-free nicotine pouches and snus.

2 Sample Preparation



Figure 2. Sample preparation for tobacco-free nicotine pouches and snus in cell culture media.

3 Test Articles

Parameter	Velo™			Commercial comparator	CORESTA reference Product 1.1
Product type	Tobacco-free nicotine pouch				Swedish Style Snus
Manufacturer	BAT			Nordic Spirit	CORESTA
Flavour	Berry Frost	Tropic Breeze	Ice Cool	Wild berry & Bergamot	N/A
Nicotine strength (per pouch)	4mg	4mg	10mg	6mg	8mg
PCODE	LYFT_BF04	LYFT_TB04	LYFT_IC10	NDSP_BW06	CRP1.1

*Velo™ previously marketed as Lyft

4 *In vitro* assays

Parameter	ToxTracker	NRU	Ames	MLA	Signaling
Cell Line	Mouse embryonic stem cell (mESC)	Mouse fibroblasts (Balb/c 3T3 clone A31)	Salmonella typhimurium (TA98, TA100, TA1535, TA1537 and TA102)	Mouse lymphoma cells (L5178Y tk+/-)	NCI-H292 lung carcinoma cells
Readout	GFP Induction	Induction of cell death	Mutation Frequency	Induction of mutations	Cytokines/ phosphoproteins
Citation	Smart et al 2022 (1)	OECD Test Guideline No. 432 (2)	OECD Test Guideline No. 471 (3)	OECD Test Guideline NO. 490 (4)	Tsolakos et al in submission (5)

Results

In vitro disease assessment: ToxTracker



CRP1.1 induced a positive response in four toxicological endpoints in the absence of S9 and three endpoints in presence of S9 (Figure 3). All NPs induced a positive response in Srxn1 +S9, with LYFT_BF04 and LYFT_TB04 inducing a positive response in Ddit3 +S9.

Figure 3. Genotoxic response of five test article extracts assessed with ToxTracker reporter cell lines. Results were shown as fold induction of the six separate biomarkers: Srxn1 & Blvrb (oxidative stress), Btg2 (cellular stress), Bscl2 & Rtkn (DNA damage) and Ddit3 (protein damage). Curves show best fit and 95 % confidence interval of the fit. Dashed line shows the 2-fold change threshold in GFP induction.

Regulatory toxicological assessment

Regulatory Assay		Velo™			Commercial Comparator	CORESTA reference product 1.1
		LYFT_BF04	LYFT_TB04	LYFT_IC10	NDSP_BW06	CRP1.1
NRU (Cytotoxicity)		X	X	X	X	X
Ames (Mutagenicity)		X	X	X	X	X
MLA (Genotoxicity)	3hrs –S9	X	X	X	X	X
	3 hrs + S9	X	X	X	X	X
	24 hrs - S9	?	X	X	X	✓

X denotes negative; **?** denotes unequivocal and ✓ denotes positive response

Potential signaling pathways and inflammatory response



Figure 7. Inflammatory response upon exposure to five test article extracts for 48 hrs. Fold changes were calculated relative to the untreated control samples using MFI values. The grey box highlights any concentration that cause the cell viability to be less than 75% due to high cytotoxicity.

Potential signalling pathways or inflammatory response



Figure 6. Experimental design and endpoints of experiments.



Figure 8. Phosphorylation signalling markers response measured at 30 mins and 2 hrs. Fold changes were calculated relative to the untreated control samples using median fluorescence intensities (MFI values).

Conclusion

This study demonstrated that a weight of evidence approach is required to cover a wide range of endpoints to provide sufficient *in vitro* data for the assessment of potential comparative risk of NP and snus.

To this end we have used a three-step approach to analyse the biological effects of NPs and reference snus extracts in the following areas: cytotoxicity, mutagenicity/ genotoxicity, and cell signalling. In summary, NPs extracts were less biologically active in all endpoints tested, compared to snus, relevant to a range of disease processes.

Taken together with previously published data on chemical analysis and clinical studies, the data presented here contribute to the weight of evidence that suggest NPs should considered as an alternative reduced risk product in comparison to snus.

Acknowledgements

The authors are grateful to Labcorp Early Development Services, Harrogate, for conduct of the NRU, MLA and Ames assay and Nicole East for nicotine quantification of test extracts and support with study initiation..

Contacts

Fan Yu, fan_yu@bat.com
Emma Bishop, emma_bishop@bat.com

References

1. Smart, D. E., et al. (2022). "Application of ToxTracker for the toxicological assessment of tobacco and nicotine delivery products." Toxicol Lett 358: 59-68. https://doi.org/10.1016/j.toxlet.2022.01.005
2. OECD (2019), Test No. 432: In Vitro 3T3 NRU Phototoxicity Test, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264071162-en.
3. OECD (2020), Test No. 471: Bacterial Reverse Mutation Test, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264071247-en.
4. OECD (2016), Test No. 490: In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris, https://doi.org/10.1787/9789264264908-en.
5. Tsolakos N. et al (2024) Comparative toxicological assessment of cigarettes and new category products via an in vitro multiplex proteomics platform, Toxicology Reports (In Submission)

Follow us:
www.bat-science.com welcometobat @BAT_Sci